Tricida, Inc. (Nasdaq: TCDA) announced an update regarding its interactions with the FDA following the End-of-Review Type A Meeting focused on its lead drug candidate, veverimer (TRC101). Veverimer is intended to treat metabolic acidosis in patients with chronic kidney disease (CKD). A conference call and webcast will be held on October 29, 2020, at 8:00 am ET to discuss FDA feedback and future plans. The condition affects an estimated three million CKD patients in the U.S. Further details are available on Tricida’s website.
Tricida, Inc. (Nasdaq: TCDA) is set to present 12 studies at the American Society of Nephrology Kidney Week 2020, highlighting the role of metabolic acidosis in chronic kidney disease (CKD). Key presentations include analyses on the relationship between metabolic acidosis and CKD progression across diverse populations, and the effects of veverimer—a treatment under investigation for metabolic acidosis. The findings aim to enhance understanding of this condition in CKD patients, particularly as there are currently no FDA-approved therapies for chronic metabolic acidosis.